In 2025, drug approvals widen treatment options for chronic diseases, infections and pain, including Ozempic kidney ...
This year has been one for the books in medicine. From Ozempic’s expanded role in protecting failing kidneys to long‑acting ...
Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial . KT-621 BROADEN2 Phase 2b AD trial ongoing, with data e ...
So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...
Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025 ...
Patients with cancer often require specialised care at centres located far from their residence. During the COVID-19 pandemic, telemedicine has rapidly gained ground as a way to ease system pressures ...
Bullous pemphigoid is a blistering autoimmune disease characterized by two hemidesmosomal proteins (anti-BP180 and 230). Pemphigus, by contrast, is characterized by two autoantibodies (anti-desmoglein ...
More patients treated with dupilumab experienced sustained disease remission and itch reduction at week 36 compared with those who received placebo. The Food and Drug Administration (FDA) has approved ...
The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that largely affects elderly patients, drugmakers Sanofi and Regeneron announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback